Vivesto Banner Image


  • Ticker OASMY
    Exchange OTC More
  • Industry Drug Manufacturers - Major More
  • Sector Healthcare More
Vivesto Logo Image
  • 51-200 Employees
  • Based in Uppsala, Sweden
Vivesto is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Vivesto’s proprietary drug delivery platform ™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs thatMore currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Vivesto’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: VIVE).
4.8 / 5.0 (91)

Vivesto reports have an aggregate usefulness score of 4.8 based on 91 reviews.


Most Recent Annual Report

MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Vivesto Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!